Opalia raises C$3.2 million to scale cell-based dairy patform

Opalia has raised CAD $3.2 million (approximately US$2.3 million) in an initial seed close to scale its cell-based dairy platform and advance commercial partnerships ahead of planned market entry.

• Opalia raised CAD $3.2 million (US$2.3 million) in a seed round led by Nàdarra Ventures with participation from multiple new and existing investors.
• The company secured paid pre-commercial pilot agreements with global dairy players, including Hoogwegt, alongside additional letters of intent across North America, Europe and Asia.
• Funding supported scale-up of a modular bioreactor system, with validation planned over 24 months ahead of targeted commercialization in 2028.

The Montreal-based foodtech, which produces real milk without cows, confirmed the round was led by Nàdarra Ventures, with participation from Spring Capital, UCEED, Anges Québec and existing investors including Investissement Québec, Cycle Momentum and BoxOne Ventures. Following strong early demand, the company has also been selectively engaging additional strategic investors.

Founded by Jennifer Côté and Lucas House, Opalia has developed a patent-pending platform that uses mammary cells to produce milk in a controlled bioreactor environment. The company stated that its process generates the proteins, fats and sugars found in conventional dairy, creating complete milk rather than individual dairy proteins that need to be reformulated into finished products.

The funding has arrived as Opalia prepares for its next phase of scale-up, including development of a larger production system based on its proprietary modular bioreactor. Over the next 24 months, the company plans to validate the system as it works toward commercialization in 2028 with Hoogwegt and other strategic partners.

“We’ve moved beyond proving the science at laboratory scale, now it’s all about scaling and proving commercial viability. With real commercial partners already at the table, we’re building the infrastructure for cell-based dairy to compete globally, not just conceptually,” said Jennifer Côté, CEO & Co-Founder of Opalia.

Opalia has already secured paid pre-commercial pilot agreements with global dairy companies, including Hoogwegt, which the company described as the world’s largest independent dairy supplier, through a two-year commercial partnership. It has also signed a paid pilot with the Canadian division of a leading global dairy group, described as one of the largest dairy companies globally by revenue and production volume.

The company has also been advancing discussions with food and dairy corporations across North America, Europe and Asia, with a pipeline of signed letters of intent that it aims to convert into additional commercial partnerships over the next two years.

Unlike precision fermentation platforms that typically produce individual milk proteins, Opalia’s approach is designed to produce complete milk. The company stated that this could allow its milk to be sold directly as fluid or powdered milk, or used by partners to make cheese, butter, ice cream and other dairy products without reformulation or changes to existing dairy processes.

Opalia is operating as a B2B ingredient platform, supplying and licensing its technology to established dairy and food companies rather than building a consumer-facing brand. The company’s stated goal is to integrate into existing dairy supply chains as a supplier of milk and milk ingredients.

The company linked its commercial strategy to rising pressure on global dairy supply, citing land access, supply chain volatility, zoonotic disease outbreaks and climate change as factors constraining conventional production. It stated that demand for dairy products is increasingly exceeding supply, creating opportunities for partnerships with major dairy companies.

“We see Opalia as a foundational player in the next era of dairy. What sets them apart is a combination of highly credible, differentiated science and a clear, executable path to scale within existing dairy infrastructure, addressing the economics required to compete globally,” said Mary Dimou, Managing Partner at Nàdarra Ventures. “Innovation is no longer optional. Today, global demand for dairy is outpacing supply, and the traditional system is under increasing pressure from climate and resource constraints. While regulatory pathways will take time, we view them as a matter of when, not if. Opalia is uniquely positioned to help define a new model of dairy production at global scale.”

Regulatory approval is now one of Opalia’s major upcoming milestones. The company has been working on North American regulatory filings, with international submissions, including in Asia and Europe, expected to follow.

Opalia stated that its partnerships already span five countries across three continents, reflecting industry interest in scalable alternatives to conventional dairy before regulatory approval and commercial launch.

“Faced with increasing pressures on dairy supply, environmental challenges, and the need to innovate in production methods, Opalia is developing an innovative Quebec-based technology that paves the way for a new generation of dairy ingredients. With the Impulsion Fund, Investissement Québec, alongside leading investors and partners, supports innovative companies that are transforming local science into concrete solutions for the economy of tomorrow,” said Alex Laverdière, Vice-President, Venture Capital, Investissement Québec.